Ładuje się......
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course ha...
Zapisane w:
| Wydane w: | Mult Scler Relat Disord |
|---|---|
| Główni autorzy: | , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Elsevier B.V.
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7307994/ https://ncbi.nlm.nih.gov/pubmed/32593961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102323 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|